It is essential that the strategy for gene therapy using E. coli PNP be demonstrated in vivo. This goal will be accomplished by (1) establishing a few appropriate in vivo tumor models, (2) selecting appropriate nucleoside analogs by toxicity and pharmacokinetic evaluations, and (3) demonstrating anticancer activity of selected nucleoside analogs in the tumor models and optimizing this activity. First, the in vivo growth of tumors transduced in vitro with the PNP gene (to be supplied by Dr. Sorscher of UAB) will be characterized. The in vivo stability of the transduction will also be determined. The tumor lines that will be studied are human D-54MG glioma, rat RT-2 glioma, murine MT-539M6 glioma, murine B16 melanoma, and murine 16/C mammary adenocarcinoma. The in vivo growth of the tumors transduced in vitro with a reporter gene (to be supplied by Dr. Sorscher) will also be characterized for comparison. All growth data will be compared with that for the nontransduced parental tumor line. Second, the plasma pharmacokinetics of a nucleoside analog and its corresponding purine will be determined after a single iv or ip injection of the nucleoside. An MTD will be also determined for the nucleoside and its purine using an appropriate treatment regimen, which will depend on the plasma pharmacokinetics of the nucleoside and the in vivo stability of the transduced PNP gene. If a nucleoside analog and its purine are found to have similar MTDs, then this nucleoside/purine pair will not be used in antitumor evaluations. Third, the anticancer activity of the selected nucleoside analog (administered ip or iv) will be evaluated against a Sc implanted tumor line transduced with the PNP gene. For comparison, the evaluation will also be conducted with the tumor line transduced with a reporter gene and with the nontransduced parental tumor line. The anticancer evaluations will be repeated with l or 2 other transduced tumor line sets if available. Detailed studies to optimize and characterize the anticancer activity of the nucleoside analog (e.g., route of administration, treatment schedule, percent of transduced cells required for activity, etc.) will be conducted using the best model. The anticancer activity observed with the PNP gene therapy will be compared with that observed with standard clinical agents for the corresponding nontransduced tumor (using our historical data base).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19CA067763-04
Application #
6103078
Study Section
Project Start
1998-09-01
Project End
1999-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
4
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Southern Research Institute
Department
Type
DUNS #
006900526
City
Birmingham
State
AL
Country
United States
Zip Code
35205
Hassan, Abdalla E A; Abou-Elkhair, Reham A I; Parker, William B et al. (2016) 6-Methylpurine derived sugar modified nucleosides: Synthesis and evaluation of their substrate activity with purine nucleoside phosphorylases. Bioorg Chem 65:9-16
Hassan, Abdalla E A; Abou-Elkhair, Reham A I; Riordan, James M et al. (2012) Synthesis and evaluation of the substrate activity of C-6 substituted purine ribosides with E. coli purine nucleoside phosphorylase: palladium mediated cross-coupling of organozinc halides with 6-chloropurine nucleosides. Eur J Med Chem 47:167-74
Tai, C-K; Wang, W; Lai, Y-H et al. (2010) Enhanced efficiency of prodrug activation therapy by tumor-selective replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene. Cancer Gene Ther 17:614-23
Kang, You-Na; Zhang, Yang; Allan, Paula W et al. (2010) Structure of grouper iridovirus purine nucleoside phosphorylase. Acta Crystallogr D Biol Crystallogr 66:155-62
Hassan, Abdalla E A; Parker, William B; Allan, Paula W et al. (2009) Regioselective metalation of 6-methylpurines: synthesis of fluoromethyl purines and related nucleosides for suicide gene therapy of cancer. Nucleosides Nucleotides Nucleic Acids 28:642-56
Sorscher, E J; Harris, J; Alexander, M et al. (2006) Activators of viral gene expression in polarized epithelial monolayers identified by rapid-throughput drug screening. Gene Ther 13:781-8
Dontsova, Maria V; Gabdoulkhakov, Azat G; Molchan, Olga K et al. (2005) Preliminary investigation of the three-dimensional structure of Salmonella typhimurium uridine phosphorylase in the crystalline state. Acta Crystallogr Sect F Struct Biol Cryst Commun 61:337-40
Silamkoti, A V; Allan, P W; Hassan, A E A et al. (2005) Synthesis and biological activity of 2-fluoro adenine and 6-methyl purine nucleoside analogs as prodrugs for suicide gene therapy of cancer. Nucleosides Nucleotides Nucleic Acids 24:881-5
Toms, Angela V; Wang, Weiru; Li, Yingbo et al. (2005) Novel multisubstrate inhibitors of mammalian purine nucleoside phosphorylase. Acta Crystallogr D Biol Crystallogr 61:1449-58
Zang, Yang; Wang, Wen-Hu; Wu, Shaw-Wen et al. (2005) Identification of a subversive substrate of Trichomonas vaginalis purine nucleoside phosphorylase and the crystal structure of the enzyme-substrate complex. J Biol Chem 280:22318-25

Showing the most recent 10 out of 29 publications